<DOC>
	<DOCNO>NCT00559676</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood tumor tissue laboratory patient cancer receive chemotherapy may help doctor understand effect chemotherapy biomarkers . It may also help doctor predict patient respond treatment . PURPOSE : This phase IV trial study biomarkers patient undergo chemotherapy metastatic colorectal cancer .</brief_summary>
	<brief_title>Study Biomarkers Patients Undergoing Chemotherapy Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Research oncogenetic parameter pharmacogenetic pharmacokinetic predictor therapeutic response toxic effect . Secondary - Study correlation pharmacogenetic pharmacokinetic parameter . - Study predictive value parameter disease-free overall survival . OUTLINE : This multicenter study . Patients receive 1 4 chemotherapy regimen : - Regimen 1 : Fluorouracil leucovorin calcium - Regimen 2 : Capecitabine leucovorin calcium - Regimen 3 : Irinotecan hydrochloride - Regimen 4 : Oxaliplatin Tumor blood sample collect start chemotherapy examine pharmacogenetic analysis . Clinical biological parameter also study . Blood sample also collect first course chemotherapy pharmacokinetic study . After completion study therapy , patient follow periodically 3 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic colorectal cancer Unresectable metastatic disease must confirm histologically &gt; 2 year since primary diagnosis Measurable metastatic disease &gt; 1 cm spiral CT scan &gt; 2 cm method Scheduled receive firstline chemotherapy metastatic disease Chemotherapy must include fluorouracil , capecitabine , irinotecan hydrochloride , oxaliplatin No inadequate unusable tissue tissue available No known brain metastasis meningeal disease PATIENT CHARACTERISTICS : WHO performance status 02 No contraindication chemotherapy Not pregnant nursing Fertile patient must use effective contraception No severe pathology likely worsen therapy No dementia severely impaired mental condition No geographical psychological reason would preclude treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior therapy metastatic cancer Prior adjuvant chemotherapy allow Concurrent bevacizumab monoclonal antibody therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
</DOC>